D2 and 5-HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 10, 1999, Pages 15-19

  Remington, Gary ^a,b   Kapur, Shitij ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Centre for Addiction   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXAPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LOXAPINE; LOXAPINE SUCCINATE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; PIRENZEPINE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ARTICLE; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT OUTCOME; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; IN VITRO STUDY; METABOLISM; REVIEW;

AMOXAPINE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; DOPAMINE ANTAGONISTS; HALOPERIDOL; HUMANS; LOXAPINE; PIRENZEPINE; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032934615     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993;19:371-429
2. Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand 1995;91(suppl 388):24-30
3. Hippius H. The history of clozapine. Psychopharmacology (Berl) 1989;99: S3-S5
4. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25:390-392
5. i values. J Pharmacol Exp Ther 1989;251:238-251
6. Kapur S, Cho R, Jones C, and the Schizophrenia PET Group. Is amoxapine an atypical antipsychotic? suggestive evidence from PET investigations of 5-HT2 and D2 receptor occupancy. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Waikoloa, Hawaii
7. 4. Neuropsychopharmacology 1992;7:261-284
8. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-950
9. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235
10. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544
11. Wolkin A, Barouche F, Wolf AP. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-908
12. Pilowsky LS, Costa DC, Ell PJ, et al. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a (+123)I IBZM SPET (single photon emission tomography) study. Psychol Med 1993;23: 791-797
13. 2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 1998;18:305-310
14. Daskalakis ZJ, Kapur S, Jones C, et al. Dopamine D2 occupancy predicts prolactin elevation: a prospective clinical-PET investigation. Presented at the International Conference of Schizophrenia Research; April 17-21, 1999; Santa Fe, New Mexico
15. 2 occupancy predict antipsychotic response and side effects? Presented at the International Congress on Schizophrenia Research; April 17-21, 1999; Santa Fe, New Mexico
16. 2 receptor occupancy and plasma levels on low doses of oral haloperidol: a PET study. Psychopharmacology (Berl) 1997;131:148-152
17. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma levels in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91
18. McEvoy JP, Hogart GE, Steingard S. Optimal dosing of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:307-316
19. Bollini P, Pampallona S, Orza MJ. et al. Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials. Psychol Med 1994;24:307-316
20. Stone CK, Garver DL, Griffith J, et al. Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 1995;152: 1210-1212
21. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-1449
22. 2 dopamine receptor occupancy in living human brain: a PET study with risperidone. Psychopharmacology (Berl) 1993;110:265-272
23. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms. Life Sci 1995;57:103-107
24. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-670
25. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 1993;265:498-508
26. Megens AAHP, Awouters FHL, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994;114:9-23
27. Nyberg S, Nakashima Y, Nordstrom A-L, et al. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Br J Psychiatry 1996;168(suppl 29):40-44
28. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-476
29. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
30. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
31. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-928
32. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293
33. Bymaster FP, Rasmussen K, Calligaro DO, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 1997;58(suppl 10):28-36
34. Leysen JE, Janssen PMF, Gommeren W, et al. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992;41: 494-508
35. 2A receptor binding of different doses of quetiapine in schizophrenia. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Waikoloa, Hawaii
36. 2 occupancy: a study of quetiapine. Presented at the International Congress on Schizophrenia Research; April 17-21, 1999; Santa Fe, New Mexico
37. Saller CF, Salarna AI, Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:285-292
38. Gudelsky GA, Frank Nash J, Berry SA, et al. Basic biology of clozapine: electrophysiological and neuroendocrinological studies. Psychopharmacology (Berl) 1989;99:S13-S17
39. Gefvert O, Bergstrom M, Langstrom B, et al. Time course of central nervous dopamine-D-2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 1998;135:119-126
40. 2 occupancy. Biol Psychiatry. In press
41. 2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997;154:1525-1529
42. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63
43. 2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 1996;15: 562-566
44. Lydiard RB, Gelenberg AJ. Amoxapine - an antidepressant with some neuroleptic properties: a review of its chemistry, animal pharmacology and toxicology, human pharmacology, and clinical efficacy. Pharmacotherapy 1981;1:163-178
45. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 1998;3:135-140
46. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl). In press
47. Gerlach J, Peacock L. New antipsychotics: the present status. Int Clin Psychopharmacol 1995;10(suppl 3):39-48
48. Waddington JL, Scully PJ, O'Callaghan E. The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophr Res 1997;28:207-222
49. Seeman P. Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand 1990;82:14-20
50. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors yet occupy high levels of these receptors. Mol Psychiatry 1998;3:123-134